Management of Hypertension and Lipid Control in Patients with Impaired Renal Function

Assessment of Renal Function

Patients with eGFR <60 mL/min/1.73m² require careful medication selection and dosing adjustments for certain medications, as recommended by the American Journal of Kidney Diseases 1, 2
Regular monitoring of kidney function is recommended at least annually, with more frequent monitoring (twice yearly) for those with eGFR 30-60 mL/min/1.73m², according to the Mayo Clinic Proceedings 2

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend statin therapy for adults aged ≥50 years with CKD not on dialysis, regardless of lipid levels, as stated in the American Journal of Kidney Diseases 1, 3
For patients with eGFR <60 mL/min/1.73m², KDIGO suggests avoiding high-intensity statins due to potential increased risk of adverse effects, as reported in the American Journal of Kidney Diseases 1
Statins have been shown to reduce cardiovascular events in patients with CKD, according to the American Journal of Kidney Diseases 4, 3

The European Heart Journal recommends a blood pressure target of <130/80 mmHg for patients with CKD, as stated in the European Heart Journal and Diabetes Care 5, 6, 7
Increasing telmisartan from 40 mg to 80 mg is appropriate for patients with uncontrolled hypertension and CKD, as recommended by the European Heart Journal and Diabetes Care 6, 7, 8
Angiotensin II receptor blockers (ARBs) like telmisartan are recommended first-line therapy for hypertension in patients with CKD, particularly with albuminuria, according to the European Heart Journal and Diabetes Care 5, 7

Monitor blood pressure regularly after dose adjustment, as recommended by the European Heart Journal and Diabetes Care 6, 7
Check renal function and electrolytes (particularly potassium) within 2-4 weeks after increasing ARB dose, as stated in the Journal of the American Society of Nephrology and Diabetes Care 9, 7
Monitor for potential adverse effects of statins, including muscle symptoms, as reported in the American Journal of Kidney Diseases 1, 4
A transient reduction in eGFR (up to 25%) may occur after initiation or dose increase of ARBs but is generally not a reason to discontinue therapy unless severe, according to the Mayo Clinic Proceedings 2

The American Journal of Kidney Diseases defines severe albuminuria as >300 mg/g, which is indicated by a random urine microalbumin >200 mg/L with a microalbumin-to-creatinine ratio >276.9 mg/g 10
The combination of renal failure and severe proteinuria suggests at least stage 3B-4 CKD (GFR 15-44 mL/min/1.73m²), according to the American Journal of Kidney Diseases and Annals of Internal Medicine 11, 12
Significant kidney damage with impaired filtration is suggested by low urine creatinine with high albumin levels, as reported in Annals of Internal Medicine 13

The American College of Physicians, as reported in Annals of Internal Medicine, recommends starting an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) as first-line therapy to reduce proteinuria and slow disease progression 14
Dietary protein restriction, sodium restriction, and statin therapy may be beneficial in reducing cardiovascular risk and slowing disease progression, according to Annals of Internal Medicine 13, 14
Avoiding nephrotoxic medications, such as NSAIDs, is recommended to prevent worsening renal function and proteinuria, as reported in Clinical Infectious Diseases 15

Regular monitoring of renal function, electrolytes, and blood pressure is necessary, with a target blood pressure of <130/80 mmHg for patients with CKD, as recommended by the American Heart Association 14
Repeat urinary albumin-to-creatinine ratio in 2-3 months to assess response to therapy, according to the American Journal of Kidney Diseases 10

Nephrology referral is appropriate for patients with severe proteinuria and renal dysfunction, as recommended by the American Journal of Kidney Diseases 11
Early referral allows for timely preparation for renal replacement therapy if disease continues to progress, according to Annals of Internal Medicine 12
Patients with significant proteinuria are at high risk for progression to end-stage renal disease and cardiovascular events, as reported in Annals of Internal Medicine 13